JAZZ Q2 2026 Earnings Call Summary

Jazz Pharmaceuticals Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: Jazz Pharmaceuticals reported record revenue of $1.2 billion, a 16% year-over-year increase.
Oncology Portfolio: Notable growth of 32% in the oncology segment.
Xywav Sales: Increased by 13% to $471 million.
Epidiolex Sales: Grew 16% year-over-year to $292 million.
Zepzelca Sales: Achieved $106 million, a 42% increase.
Non-GAAP Adjusted EPS: Reported at $5.71, including IPR&D charges of $0.94.
Operating Cash Flow: Generated $824 million in the first half of the year.
2026 Revenue Guidance: Revised upward to $4.60 billion to $4.75 billion.

2. Strategic Updates and Business Highlights

Zanidatamab: Anticipated PDUFA date on August 25, 2026, with preparations for launch in HER2-positive metastatic gastric and gastroesophageal adenocarcinoma (GEA).
Collaboration with AbCellera: Focus on T-cell engagers to enhance oncology pipeline.
Xywav: Continued strong demand with a focus on patient support services and digital marketing.
Epidiolex: Expansion into new formulations and indications, including a novel capsule to improve patient compliance.
Ziihera: Successful launch in biliary tract cancer (BTC) with over 50% market share in the U.S.

3. Forward Guidance and Outlook

Revenue Growth: Expecting double-digit growth for Xywav in 2026, with rare sleep revenue projected between $2.025 billion and $2.125 billion.
Investment in R&D: Continued focus on clinical trials for Epidiolex and zanidatamab, with multiple upcoming readouts.
SG&A Expenses: Modestly increased to support strategic investments in commercial capabilities.

4. Bad News, Challenges, or Points of Concern

Gross Margin Decline: Slight decrease due to higher sales of Zepzelca and Modeyso, which carry third-party royalties.
Generic Competition: Monitoring potential impacts from high sodium generics on Xywav, although current uptake has been limited.
Zepzelca Second-Line Business Erosion: Anticipated decline in second-line sales as patients transition to first-line treatments.
Tax Rate Increase: Non-GAAP adjusted effective tax rate higher than guidance due to shifts in geographic income mix.

5. Notable Q&A Insights

Epidiolex Performance: Strong demand in both pediatric and adult segments, with no unusual inventory movements noted.
Zanidatamab Approval Confidence: High confidence in approval ahead of the PDUFA date, with strong clinical data supporting its use.
Xywav Durability: Despite potential competition from orexin agents, Xywav's unique low sodium profile is expected to maintain its market position.
Market Dynamics in GEA: Anticipated strong uptake in GEA due to established relationships and existing market presence from BTC.
Business Development Strategy: Ongoing interest in rare diseases, with a focus on unmet needs and leveraging existing expertise.

This summary encapsulates the key aspects of Jazz Pharmaceuticals' Q2 2026 earnings call, highlighting financial performance, strategic initiatives, future guidance, and challenges faced by the company.

JAZZ — Jazz Pharmaceuticals plc